Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

Abstract: The invention relates to crystalline forms of a ?-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.

Abstract: A device (9) for remotely monitoring at least one medical device (7) includes at least one portion (11) that vibrates when the medical device is used by a patient in order to receive a medical treatment. The monitoring device (9) includes: at least one sensor (15) intended to be in mechanical contact with the portion and suitable for detecting vibrations and for producing a primary electric or radio-electric signal (23) representing vibrations, and a local processing unit (13) suitable for receiving and extracting from the primary signal, at least one information item representing a duration of use of the medical device by the patient, and for producing at least one secondary signal (29) containing the information, the secondary signal being intended to be sent to at least one remote server (3) suitable for receiving and for extracting from the secondary signal, the information.

Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumor activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

Abstract: The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.

Abstract: The present invention relates to new crystalline forms of a purine derivative which exhibits excellent anti-tumour activity. The invention also relates to a pharmaceutical composition containing said crystalline forms as an active ingredient, and use thereof in the prevention or treatment of disease. The invention further relates to a process for preparing the crystalline forms.

Abstract: A device (9) for remotely monitoring at least one medical device (7) includes at least one portion (11) that vibrates when the medical device is used by a patient in order to receive a medical treatment. The monitoring device (9) includes: at least one sensor (15) intended to be in mechanical contact with the portion and suitable for detecting vibrations and for producing a primary electric or radio-electric signal (23) representing vibrations, and a local processing unit (13) suitable for receiving and extracting from the primary signal, at least one information item representing a duration of use of the medical device by the patient, and for producing at least one secondary signal (29) containing the information, the secondary signal being intended to be sent to at least one remote server (3) suitable for receiving and for extracting from the secondary signal, the information.

Abstract: The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.